Methods of treating heart failure with reduced ejection fraction using dapagliflozin

A technology for heart failure and purpose, applied in pharmaceutical formulations, organic active ingredients, cardiovascular system diseases, etc., can solve problems such as poor five-year survival rate, and achieve the effect of reducing risks

Active Publication Date: 2021-02-09
ASTRAZENECA AB
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But even with the best possible treatments, HF has a worse five-year survival rate than most cancers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating heart failure with reduced ejection fraction using dapagliflozin
  • Methods of treating heart failure with reduced ejection fraction using dapagliflozin
  • Methods of treating heart failure with reduced ejection fraction using dapagliflozin

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0260] DAPA-HF phase III clinical trial results

[0261] Introduction

[0262] A large clinical trial involving participants with type 2 diabetes (T2D) has shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure (HF). 1-4 However, it is worth noting that the majority of patients in these trials did not have HF at baseline, and the benefit of SGLT2 inhibitor treatment largely reflected the prevention of HF events. Notably, the reduction in hospitalization for heart failure was observed early after randomization, raising the possibility of one or more mechanisms of action different from those commonly assumed to explain the cardiovascular effects of glucose-lowering therapy. Beneficial mechanism of action. 5-9 In addition to the diuretic and associated hemodynamic effects of SGLT2 inhibitors, effects on myocardial metabolism, ion transporters, fibrosis, adipokines, and uric acid have also been proposed. 5-9 Most of the...

example 2

[0344] DAPA-HF phase III clinical trial results - the effect of dapagliflozin on HF symptoms, health status and quality of life

[0345] Introduction

[0346] Patients with HF and HFrEF are at high risk of disease progression, leading to clinical deterioration, rehospitalization, and death. Bui, A.L. et al., NatRev Cardiol 8:30-41 (2011). Importantly, they also carry the burden of debilitating symptoms, which affect their daily function and quality of life. Indeed, some treatments for HFrEF have positive effects on death and hospitalization, but do not improve health outcomes (Reddy, P. and Dunn, A.B., Pharmacotherapy 20:679-689 (2000), which emphasizes There is a high unmet need for additional effective therapies that not only improve clinical events but also reduce symptom burden and physical limitations and improve quality of life.In fact, improving the health status of patients is a key goal of heart failure management, which is increasingly recognized by practice guidel...

example 3

[0379] DAPA-HF Phase IH Trial Results - Effects of Dapagliflozin on Clinical, Metabolic, Hemodynamic and Renal Outcomes in HF Patients With and Without Diabetes

[0380] Introduction

[0381] In the DAPA-HF trial discussed in Example 1, it was demonstrated that SGLT2 inhibition resulted in a similar reduction in the primary outcome of exacerbation of HF events or death from cardiovascular causes in HF patients with and without diabetes. See also McMurray, J.J.V. et al., Eur J Heart Fail 21:665-675 (2019); McMurray, J.J.V. et al., NEngl J Med [New England Journal of Medicine] doi:10.1056 / NEJMoa1911303 [before printing Electronic Edition] (September 19, 2019), which is incorporated by reference in its entirety. In the prespecified analysis presented in this Example, the efficacy and safety of dapagliflozin and the metabolic and hemodynamic changes.

[0382] method

[0383] Eligibility requirements, baseline characteristics, and exclusion criteria for DAPA-HF study patients a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to methods of treating heart failure with reduced ejection fraction using dapagliflozin. The methods disclosed herein may reduce the risk of complex outcome of death resulting from a first onset or cardiovascular cause of worsening heart failure (due to heart failure hospitalization or emergency heart failure treatment). Each of the three compositions of this composite result, as well as the total number of deaths caused by heart failure hospitalization and cardiovascular reasons, may also be reduced. An SGLT2 inhibitor, such as dapagliflozin, may also reduce worsening of symptoms of heart failure. The methods disclosed herein may also improve heart failure symptoms, health, and quality of life.

Description

[0001] This case is a divisional application of a patent application with an application date of March 9, 2020, an application number of 202080000531.4, and an invention titled "Method for Treating Heart Failure with Reduced Ejection Fraction Using Dapagliflozin". technical field [0002] The invention relates to a method for using dapagliflozin to treat heart failure with reduced ejection fraction. Background technique [0003] Heart failure (HF) is a life-threatening medical condition in which the heart cannot adequately pump enough blood to maintain the body's organs. HF affects approximately 64 million people worldwide (half of whom have reduced ejection fraction (HFrEF)), and the prevalence and incidence of HF continue to increase worldwide. (Cannie D.E. et al., European Cardiology Review 14(2):89-96 (2019)). HF is a chronic degenerative disease in which half of patients die within five years of diagnosis (Mamas, M.A. et al., European Journal of Heart Failure 19:1095-1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/351A61P9/04
CPCA61K31/351A61P9/04
Inventor A·M·兰吉尔德
Owner ASTRAZENECA AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap